Skip to main content
SpringerLink
Log in

Black-Box Warnings of Antiseizure Medications: What is Inside the Box?

  • Review Article
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Antiseizure medications can cause serious adverse reactions and have deleterious drug interactions that often complicate the clinical management of patients. When the US Food and Drug Administration (FDA) wants to alert healthcare providers and patients about the risk of potentially serious or fatal drug reactions, the FDA requires the manufacturers of these medications to format these warnings within a “black-box” border, and prominently display this box on the first section of the package insert; such warnings are called “black-box warnings (BBWs)”. The BBW is a way for the FDA to urge physicians to evaluate patients more rigorously and carefully weigh the risks and benefits, before prescribing medication that has the potential to cause serious adverse reactions, and to formulate a plan for close monitoring during therapy. The FDA BBW provides the extra layer of safety but many healthcare providers fail to comply with these warnings. Currently, there are 26 FDA-approved antiseizure medications in the US market, 38% of which have received BBWs, and most of the antiseizure medications with BBWs are older-generation drugs. Some antiseizure medications have multiple BBWs; for example, valproic acid has three BBWs including hepatotoxicity, fetal risk, and pancreatitis, carbamazepine has BBWs of serious skin and hematological reactions, and felbamate also has two BBWs including hepatic failure and aplastic anemia. The purpose of this review is to provide insight into each BBW received by antiseizure medications and discuss the FDA recommendations for evaluating the drug benefit/risk, and for monitoring parameters before the initiation of and during treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):357–75.

    Article  Google Scholar 

  2. Smith PEM. Initial management of seizure in adults. N Engl J Med. 2021;385(3):251–63.

    Article  PubMed  Google Scholar 

  3. McNamara JO. Emerging insights into the genesis of epilepsy. Nature. 1999;399(6738 Suppl):A15-22.

    Article  CAS  PubMed  Google Scholar 

  4. Devinsky O. Sudden, unexpected death in epilepsy. N Engl J Med. 2011;365(19):1801–11.

    Article  CAS  PubMed  Google Scholar 

  5. Sander JW. Comorbidity and premature mortality in epilepsy. Lancet. 2013;382(9905):1618–9.

    Article  PubMed  Google Scholar 

  6. Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689–701.

    Article  PubMed  Google Scholar 

  7. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68–82.

    Article  CAS  PubMed  Google Scholar 

  8. Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia. 2010;51(Suppl 3):154–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327(13):1269–81.

    Article  CAS  PubMed  Google Scholar 

  10. Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884–98.

    Article  PubMed  Google Scholar 

  11. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–86.

    Article  PubMed  Google Scholar 

  12. Brewer T, Colditz G. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824–9.

    Article  CAS  PubMed  Google Scholar 

  13. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358(13):1354–61.

    Article  CAS  PubMed  Google Scholar 

  14. Porter RJ, Cereghino JJ, Gladding GD, Hessie BJ, Kupferberg HJ, Scoville B, White BG. Antiepileptic drug development program. Cleve Clin Q. 1984;51(2):293–305.

    Article  CAS  PubMed  Google Scholar 

  15. Krall RL, Penry JK, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: I. History and a program for progress. Epilepsia. 1978;19(4):393–408.

    Article  CAS  PubMed  Google Scholar 

  16. Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals (Basel). 2010;3(7):2090–110.

    Article  CAS  PubMed  Google Scholar 

  17. Chiron C, Dulac O. Epilepsy: vigabatrin treatment and visual field loss. Nat Rev Neurol. 2011;7(4):189–90.

    Article  CAS  PubMed  Google Scholar 

  18. Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12(10):757–76.

    Article  PubMed  Google Scholar 

  19. CFR (Code of federal regulations): specific requirements on content and format of labeling for human prescription drugs biological products. 21CFR201.57. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=201.57. Accessed 28 Feb 2023.

  20. Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53(3):403–11.

    CAS  PubMed  Google Scholar 

  21. Cheng CM, Guglielmo BJ, Maselli J, Auerbach AD. Coverage of FDA medication boxed warnings in commonly used drug information resources. Arch Intern Med. 2010;170(9):831–3.

    Article  PubMed  Google Scholar 

  22. Avorn J, Kesselheim A, Sarpatwari A. The FDA Amendments Act of 2007 assessing its effects a decade later. N Engl J Med. 2018;379(12):1097–9.

    Article  PubMed  Google Scholar 

  23. O’Connor NR. FDA boxed warnings: how to prescribe drugs safely. Am Fam Physician. 2010;81(3):298–303.

    PubMed  Google Scholar 

  24. Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates DW. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med. 2006;166(3):338–44.

    Article  PubMed  Google Scholar 

  25. Kloet MA, Lohr BR, Smithburger PL, Seybert AL, Kane-Gill SL. Prospective assessment of inpatient boxed warning prescriber adherence. J Patient Saf. 2017;13(1):25–30.

    Article  PubMed  Google Scholar 

  26. Stevens JR, Jarrahzadeh T, Brendel RW, Stern TA. Strategies for the prescription of psychotropic drugs with black box warnings. Psychosomatics. 2014;55(2):123–33.

    Article  PubMed  Google Scholar 

  27. US National Library of Medicine. DailyMed current medication information. https://dailymed.nlm.nih.gov/dailymed/index.cfm. Accessed 28 Feb 2023.

  28. PDR® (Physicians’ Desk Reference®) electronic library 2022. https://www.pdr.net/. Accessed 28 Feb 2023.

  29. US Food and Drug Administration. Drugs@FDA. FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 28 Feb 2023.

  30. US Food and Drug Administration. FDA drug safety-related labeling changes database. https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/. Accessed 28 Feb 2023.

  31. US Food and Drug Administration. FDA label: full-text search of drug product labeling. https://nctr-crs.fda.gov/fdalabel/ui/search. Accessed 28 Feb 2023.

  32. Lexi-Comp®. Wolters Kluwer. http://www.crlonline.com. Accessed 28 Feb 2023.

  33. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet. 2001;357(9251):216–22.

    Article  CAS  PubMed  Google Scholar 

  34. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802.

    Article  CAS  PubMed  Google Scholar 

  35. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012;380(9848):1180–92.

    Article  PubMed  Google Scholar 

  36. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, Detyniecki K. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24–31.

    Article  PubMed  Google Scholar 

  37. Alsfouk BAA, Brodie MJ, Walters M. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurol. 2020;77(5):574–81.

    Article  PubMed  Google Scholar 

  38. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016;68(3):563–602.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Devinsky O, Vezzani A, O’Brien TJ, Jette N, Scheffer IE, de Curtis M, et al. Epilepsy. Nat Rev Dis Primers. 2018;4:18024.

    Article  PubMed  Google Scholar 

  40. Boylan LS, Devinsky O, Barry JJ, Ketter TA. Psychiatric uses of antiepileptic treatments. Epilepsy Behav. 2002;3(5S):54–9.

    Article  PubMed  Google Scholar 

  41. Wieshmann UC, Baker GA. Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register. BMJ Open. 2013;3(3): e002564.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022;36(10):1079–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res. 2016;126:201–10.

    Article  CAS  PubMed  Google Scholar 

  44. Fycompa® (perampanel) tablets. CIII. FDA approved labeling text dated April 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf. Accessed 14 Feb 2023.

  45. Pack AM. Perampanel: another choice for patients with idiopathic generalized epilepsy who have tonic-clonic seizures. Epilepsy Curr. 2016;16(1):27–8.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.

    Article  CAS  PubMed  Google Scholar 

  47. Bermeo-Ovalle A. Making rash decisions in epilepsy: evaluating hypersensitivity reactions to anti-seizure medications. Epilepsy Curr. 2019;19(2):96–8.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999;353:2190–4.

    Article  CAS  PubMed  Google Scholar 

  49. Guvenir H, Dibek Misirlioglu E, Civelek E. The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study. J Allergy Clin Immunol Pract. 2018;6(6):2043–50.

    Article  PubMed  Google Scholar 

  50. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80:194–200.

    Article  CAS  PubMed  Google Scholar 

  51. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995;155(21):2285–90.

    Article  CAS  PubMed  Google Scholar 

  52. Blaszczyk B, Lason W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67(3):426–34.

    Article  CAS  PubMed  Google Scholar 

  53. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–7.

    Article  CAS  PubMed  Google Scholar 

  54. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–85.

    Article  CAS  PubMed  Google Scholar 

  55. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.

    Article  CAS  PubMed  Google Scholar 

  56. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in. Han Chinese Epilepsia. 2007;48:1015–8.

    Article  CAS  PubMed  Google Scholar 

  57. Carbatrol® (carbamazepine) extended-release capsules label. FDA approved labeling text dated Dec, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020712s037lbl.pdf. Accessed 10 Feb 2023.

  58. Chen P, Lin JJ, Lu CS, Ong CT. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33.

    Article  CAS  PubMed  Google Scholar 

  59. Phillips EJ, Mallal SA. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med. 2011;365(7):672.

    Article  CAS  PubMed  Google Scholar 

  60. Fowler T, Bansal AS, Lozsádi D. Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting. Seizure. 2019;72:61–70.

    Article  PubMed  Google Scholar 

  61. Wadelius M, Karlsson T, Wadelius C. Lamotrigine and toxic epidermal necrolysis. Lancet. 1996;348(9033):1041.

    Article  CAS  PubMed  Google Scholar 

  62. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 2004;3:61821.

    Article  Google Scholar 

  63. LAMICTAL (lamotrigine) label. FDA approved labeling text dated March, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020241s064,020764s057,022251s028lbl.pdf. Accessed 9 Feb 2023.

  64. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345(8948):476–9.

    Article  CAS  PubMed  Google Scholar 

  65. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347–56.

    Article  CAS  PubMed  Google Scholar 

  66. Guberman AH, Besag FM, Brodie MJ. Lamotrigine associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40:985–91.

    Article  CAS  PubMed  Google Scholar 

  67. Aiken CB, Orr C. Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont). 2010;7(5):27–32.

    PubMed  Google Scholar 

  68. Serrani Azcurra DJ. Lamotrigine rechallenge after a skin rash: a combined study of open cases and a meta-analysis. Rev Psiquiatr Salud Ment. 2013;6(4):144–9.

    Article  PubMed  Google Scholar 

  69. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure. 2000;9(4):282–6.

    Article  CAS  PubMed  Google Scholar 

  70. Lorberg B, Youssef NA, Bhagwagar Z. Lamotrigine-associated rash: to rechallenge or not to rechallenge? Int J Neuropsychopharmacol. 2009;12(2):257–65.

    Article  CAS  PubMed  Google Scholar 

  71. Tomson T, Battino D, Bromley R, Kochen S. Management of epilepsy in pregnancy: a report from the nternational league against epilepsy task force on women and pregnancy. Epileptic Disord. 2019;21(6):497–517.

    PubMed  Google Scholar 

  72. MacDonald SC, Bateman BT, McElrath TF. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA Neurol. 2015;72(9):981–8.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Sveberg L, Svalheim S, Taubøll E. The impact of seizures on pregnancy and delivery. Seizure. 2015;28:35–8.

    Article  PubMed  Google Scholar 

  74. Voinescu PE, Park S, Chen LQ, Stowe ZN, Newport DJ. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018;91(13):e1228–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Pennell PB, French JA, May RC, Gerard E, MONEAD Study Group. Changes in seizure frequency and antiepileptic therapy during pregnancy. N Engl J Med. 2020;383(26):2547–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Becker DA. Pregnancy effects on seizure frequency: to seize or not to seize. Epilepsy Curr. 2021;21(5):320–2.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Meador KJ, Loring DW. Risks of in utero exposure to valproate. JAMA. 2013;309(16):1730–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Wartman C, Van den Berg A. Valproate: not all boxed warnings are created equal. Ann Pharmacother. 2022;56:1349–55.

    Article  PubMed  Google Scholar 

  79. Buehler BA, Delimont D, van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med. 1990;322(22):1567–72.

    Article  CAS  PubMed  Google Scholar 

  80. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344(15):1132–8.

    Article  CAS  PubMed  Google Scholar 

  81. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360(16):1597–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Moores G, D’Souza R, Bui E. Antiseizure medications and pregnancy. CMAJ. 2021;193(32):E1253.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Harden CL, Meador KJ, Pennell PB, et al. American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Jentink J, Loane MA, Dolk H. EUROCAT Antiepileptic Study Working Group Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–93.

    Article  CAS  PubMed  Google Scholar 

  85. Tomson T, Battino D, Bonizzoni E, Craig J. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8.

    Article  CAS  PubMed  Google Scholar 

  86. Hernández-Díaz S, McElrath TF, Pennell PB. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol. 2017;82(3):457–65.

    Article  PubMed  Google Scholar 

  87. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Tomson T, Bromley R. Association of fetal exposure to newer antiseizure medications with neurodevelopment: a step toward a better understanding. JAMA Neurol. 2021;78(8):911–3.

    Article  PubMed  Google Scholar 

  89. Sen A, Nashef L. New regulations to cut valproate-exposed pregnancies. Lancet. 2018;392(10146):458–60.

    Article  PubMed  Google Scholar 

  90. Abe K, Hamada H, Yamada T. Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. Seizure. 2014;23(2):112–6.

    Article  PubMed  Google Scholar 

  91. Pennell PB. Prescribing antiepileptic drugs to women of reproductive age. Lancet Neurol. 2018;17(6):485–6.

    Article  PubMed  Google Scholar 

  92. Betts T, Fox C. Proactive pre-conception counselling for women with epilepsy: is it effective? Seizure. 1999;8:322–7.

    Article  CAS  PubMed  Google Scholar 

  93. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–44.

    Article  CAS  PubMed  Google Scholar 

  94. Murphy S, Roberts R. “Black box” 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol. 2006;117(1):34–9.

    Article  PubMed  Google Scholar 

  95. Reuben A, Koch DG, Lee WM. Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76.

    Article  PubMed  Google Scholar 

  96. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008;118(5):281–90.

    Article  PubMed  Google Scholar 

  97. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009;15(7):719–29.

    Article  PubMed  Google Scholar 

  98. Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–56.

    Article  CAS  PubMed  Google Scholar 

  99. Chalasani N, Bonkovsky HL, Stine JG, Gu J, Barnhart H. Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. J Hepatol. 2022;76(4):832–40.

    Article  CAS  PubMed  Google Scholar 

  100. Felbatol® (felbamate) label. FDA approved labeling text dated Aug 27, 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf. Accessed 14 Feb 2023.

  101. Depacon (valproate sodium) for injection label. FDA approved labeling text dated May, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020593s041lbl.pdf. Accessed 14 Feb 2023.

  102. Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996;46(2):465–9.

    Article  PubMed  Google Scholar 

  103. Ware S, Millward-Sadler GH. Acute liver disease associated with sodium valproate. Lancet. 1980;2(8204):1110–3.

    Article  CAS  PubMed  Google Scholar 

  104. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology. 1982;2:591–7.

    Article  CAS  PubMed  Google Scholar 

  105. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut. 1984;25(6):673–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Krähenbühl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut. 1995;37(1):140–3.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Clin Toxicol. 2002;40:789–801.

    CAS  Google Scholar 

  108. Koch-Weser J, Browne TR. Drug therapy: valproic acid. N Engl J Med. 1980;302(12):661–6.

    Article  CAS  PubMed  Google Scholar 

  109. Coulter DL. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet. 1984;1(8378):689.

    Article  CAS  PubMed  Google Scholar 

  110. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52(5):1791–6.

    Article  CAS  PubMed  Google Scholar 

  111. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia. 1987;28:S23–9.

    Article  PubMed  Google Scholar 

  112. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156–64.

    Article  PubMed  Google Scholar 

  113. Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23–36.

    Article  PubMed  Google Scholar 

  114. Au JS, Pockros PJ. Drug-induced liver injury from antiepileptic drugs. Clin Liver Dis. 2013;17(4):687–97.

    Article  PubMed  Google Scholar 

  115. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. U.S. experience since 1984. Neurology. 1989;139:201–7.

    Article  Google Scholar 

  116. Wall M, Baird-Lambert J, Buchanan N, Farrell G. Liver function tests in persons receiving anticonvulsant medications. Seizure. 1992;1(3):187–90.

    Article  CAS  PubMed  Google Scholar 

  117. Sachdeo RC. Felbamate. Lancet. 1993;342(8866):300.

    Article  CAS  PubMed  Google Scholar 

  118. Brodie MJ. Felbamate: a new antiepileptic drug. Lancet. 1993;341:1445–6.

    Article  CAS  PubMed  Google Scholar 

  119. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 1999;52(8):1540–5.

    Article  CAS  PubMed  Google Scholar 

  120. Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for lennox-gastaut syndrome: current and future strategies. CNS Drugs. 2021;35(1):61–83.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res. 2006;71(2–3):89–101.

    Article  PubMed  Google Scholar 

  122. Kapetanovic IM, Torchin CD, Strong JM. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact. 2002;142(1–2):119–34.

    Article  CAS  PubMed  Google Scholar 

  123. Shah YD, Singh K, Friedman D, Devinsky O, Kothare SV. Evaluating the safety and efficacy of felbamate in the context of a black box warning: a single center experience. Epilepsy Behav. 2016;56:50–3.

    Article  PubMed  Google Scholar 

  124. Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: a review. JAMA. 2021;325(4):382–90.

    Article  CAS  PubMed  Google Scholar 

  125. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31(10):823–37.

    Article  CAS  PubMed  Google Scholar 

  126. Forsmark CE, Vege SS, Wilcox CM. Acute pancreatitis. N Engl J Med. 2016;375(20):1972–81.

    Article  CAS  PubMed  Google Scholar 

  127. Boxhoorn L, Voermans RP, Bouwense SA. Acute pancreatitis. Lancet. 2020;396(10252):726–34.

    Article  PubMed  Google Scholar 

  128. Batalden PB, Van Dyne BJ, Cloyd J. Pancreatitis associated with valproic acid therapy. Pediatrics. 1979;64:520–2.

    Article  CAS  PubMed  Google Scholar 

  129. Camfield PR. Pancreatitis due to valproic acid. Lancet. 1979;1:1198–9.

    Article  CAS  PubMed  Google Scholar 

  130. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5(6):648–61.

    Article  PubMed  Google Scholar 

  131. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet. 2008;371(9607):143–52.

    Article  PubMed  Google Scholar 

  132. Gerstner T, Büsing D, Bell N, Longin E, Kasper JM, Klostermann W, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol. 2007;42(1):39–48.

    Article  CAS  PubMed  Google Scholar 

  133. Chapman SA, Wacksman GP, Patterson BD. Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy. 2001;21(12):1549–60.

    Article  CAS  PubMed  Google Scholar 

  134. Meczker Á, Hanák L, Párniczky A, Szentesi A, Erőss B, Hegyi P. Hungarian Pancreatic Study Group. Analysis of 1060 cases of drug-induced acute pancreatitis. Gastroenterology. 2020;159(5):1958-61.e8.

    Article  PubMed  Google Scholar 

  135. Sanfey H, Bulkely GB, Cameron JL. The role of oxygen derived free radicals in the pathogenesis of acute pancreatitis. Ann Surg. 1984;200:405–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. Pediatrics. 2006;118(4):1660–3.

    Article  PubMed  Google Scholar 

  137. Zaccara G, Lattanzi S, Brigo F. Cardiac adverse effects of antiseizure medications. Expert Opin Drug Saf. 2022;21(5):641–52.

    Article  CAS  PubMed  Google Scholar 

  138. Verrier RL, Pang TD, Nearing BD, Schachter SC. The epileptic heart: concept and clinical evidence. Epilepsy Behav. 2020;105: 106946.

    Article  PubMed  Google Scholar 

  139. Bardai A, Lamberts RJ, Blom MT, Spanjaart AM, Berdowski J, van der Staal SR, et al. Epilepsy is a risk factor for sudden cardiac arrest in the general population. PLoS ONE. 2012;7(8): e42749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Kapur J, Elm J, Chamberlain JM, Barsan W. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Wu K, Hirsch LJ, Babl FE, Josephson SA. Choosing anticonvulsant medications to manage status epilepticus. N Engl J Med. 2020;382(26):2569–72.

    Article  PubMed  Google Scholar 

  142. Aaronson PM, Belgado BS, Spillane JP, Kunisaki TA. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED. Am J Emerg Med. 2011;29(9):983–8.

    Article  PubMed  Google Scholar 

  143. Kilarski DJ, Buchanan C, Von Behren L. Soft-tissue damage associated with intravenous phenytoin. N Engl J Med. 1984;311(18):1186–7.

    Article  CAS  PubMed  Google Scholar 

  144. Trinka E, Höfler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499–521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Gellerman GL, Martinez C. Fatal ventricular fibrillation following intravenous sodium diphenylhydantoin therapy. JAMA. 1967;200(4):337–8.

    Article  CAS  PubMed  Google Scholar 

  146. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures: recommendations for usage. JAMA. 1983;249(6):762–5.

    Article  CAS  PubMed  Google Scholar 

  147. Guldiken B, Rémi J, Noachtar S. Cardiovascular adverse effects of phenytoin. J Neurol. 2016;263(5):861–70.

    Article  CAS  PubMed  Google Scholar 

  148. US FDA. Phenytoin sodium injection label. FDA approved labeling text dated Feb, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=035a8d4e-2063-4240-83cb-d7eebcabe301. Accessed 14 Feb 2023.

  149. Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol. 1988;28(11):1023–32.

    Article  CAS  PubMed  Google Scholar 

  150. DeToledo JC, Lowe MR, Rabinstein A, Villaviza N. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. Epilepsia. 2001;42(2):288.

    Article  CAS  PubMed  Google Scholar 

  151. Kim D, Kim JM, Cho YW. Antiepileptic drug therapy for status epilepticus. J Clin Neurol. 2021;17(1):11–9.

    Article  PubMed  Google Scholar 

  152. Leppik IE, Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM, et al. Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. Neurology. 1990;40(3 Pt 1):456–60.

    Article  CAS  PubMed  Google Scholar 

  153. Browne TR. Fosphenytoin (Cerebyx). Clin Neuropharmacol. 1997;20(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  154. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004;11(3):244–52.

    Article  PubMed  Google Scholar 

  155. Patel SI, Birnbaum AK, Cloyd JC, Leppik IE. Intravenous and intramuscular formulations of antiseizure drugs in the treatment of epilepsy. CNS Drugs. 2015;29(12):1009–22.

    Article  CAS  PubMed  Google Scholar 

  156. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996;46(6 Suppl 1):S3-7.

    Article  CAS  PubMed  Google Scholar 

  157. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.

    Article  PubMed  PubMed Central  Google Scholar 

  158. Cerebyx® (fosphenytoin sodium) injection. FDA approved labeling tText dated April, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020450s046lbl.pdf. Accessed 14 Feb 2023.

  159. Meek PD, Davis SN, Collins DM, Gidal BE, Rutecki PA, Burstein AH, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Panel on Nonemergency Use of Parenteral Phenytoin Products. Arch Intern Med. 1999;159(22):2639–44.

    Article  CAS  PubMed  Google Scholar 

  160. Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. Neurol Sci. 2014;35(7):983–93.

    Article  CAS  PubMed  Google Scholar 

  161. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997;38(12):1265–9.

    Article  CAS  PubMed  Google Scholar 

  162. Tohen M, Castillo J, Baldessarini RJ, Zarate C Jr, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995;152(3):413–8.

    Article  CAS  PubMed  Google Scholar 

  163. Livingston S, Villamater C, Sakata Y, Pauli LL. Use of carbamazepine in epilepsy: results in 87 patients. JAMA. 1967;200(3):204–8.

    Article  CAS  PubMed  Google Scholar 

  164. Ibáñez L, Vidal X. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–74.

    Article  PubMed  Google Scholar 

  165. Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am J Psychiatry. 1984;141:687–8.

    Article  CAS  PubMed  Google Scholar 

  166. PDR.net (the Physicians’ Desk Reference), 2023. Carbamazepine: drug summary. https://www.pdr.net/drug-summary/Carbatrol-carbamazepine-2516. Accessed 13 February 2023.

  167. Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. 2006;47(7):1232–6.

    Article  PubMed  Google Scholar 

  168. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine’s hematologic reactions and monitoring recommendations. Ann Pharmacother. 1990;24(12):1214–9.

    CAS  Google Scholar 

  169. Physicians’ desk reference. 29th edn. Oradell (NJ): Medical Economics; 1975: p. 805–6.

  170. Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol. 1982;11(3):309–12.

    Article  CAS  PubMed  Google Scholar 

  171. Camfield P, Camfield C, Dooley J, Farrell K, Humphreys P, Langevin P. Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value. CMAJ. 1989;140(11):1303–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  172. Silverstein FS, Boxer L, Johnston MV. Hematological monitoring during therapy with carbamazepine in children. Ann Neurol. 1983;13(6):685–6.

    Article  CAS  PubMed  Google Scholar 

  173. Balon R, Berchou R. Hematologic side effects of psychotropic drugs. Psychosomatics. 1986;27(2):119–20 (125–7).

    Article  CAS  PubMed  Google Scholar 

  174. Daughton JM, Padala PR, Gabel TL. Careful monitoring for agranulocytosis during carbamazepine treatment. Prim Care Companion J Clin Psychiatry. 2006;8(5):310–1.

    PubMed  PubMed Central  Google Scholar 

  175. El-Shimi OS, et al. Carbamazepine-induced hematological and immunological alterations in Egyptian children with idiopathic generalized seizures. J Child Sci. 2021;11:e265–72.

    Article  Google Scholar 

  176. Shi LL, Bresnahan R, Martin-McGill KJ. Felbamate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2019;8(8): CD008295.

    PubMed  Google Scholar 

  177. Borowicz KK, Piskorska B, Kimber-Trojnar Z, Małek R, Sobieszek G, Czuczwar SJ. Is there any future for felbamate treatment? Pol J Pharmacol. 2004;56(3):289–94.

    CAS  PubMed  Google Scholar 

  178. Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021;4(4): CD003277.

    PubMed  Google Scholar 

  179. Hilton EJ, Hosking SL, Betts T. The effect of antiepileptic drugs on visual performance. Seizure. 2004;13(2):113–28.

    Article  PubMed  Google Scholar 

  180. Hu W, Chen L, Li H, Liu J. Eye disorders associated with newer antiepileptic drugs: a real-world disproportionality analysis of FDA adverse event reporting system. Seizure. 2022;96:66–73.

    Article  PubMed  Google Scholar 

  181. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314(7075):180–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  182. Sabril® (vigabatrin) tablets. FDA approved labeling text dated October 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020427s025,022006s026lbl.pdf Accessed 14 Feb 2023.

  183. Elferink AJ, Toivonen M, van Bronswijk H. Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products. Lancet. 1999;354(9187):1387–8.

    Article  CAS  PubMed  Google Scholar 

  184. Baulac M, Bordmann JP, Lanoé Y. Severe visual field construction and side-effects of GBA-mimetic antiepileptic agents. Lancet. 1998;352:546.

    Article  CAS  PubMed  Google Scholar 

  185. Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ. 1998;316:233.

    CAS  PubMed  PubMed Central  Google Scholar 

  186. Iannetti P, Spalice A, Perla FM, Conicella E, Raucci U, Bizzarri B. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics. 2000;106(4):838–42.

    Article  CAS  PubMed  Google Scholar 

  187. Sarpatwari A, Brown BL, McGraw SA, Dejene SZ, Abdurrob A, Santiago Ortiz AJ, et al. Patient and caregiver experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. JAMA Netw Open. 2022;5(1): e2144386.

    Article  PubMed  PubMed Central  Google Scholar 

  188. Odi R, Invernizzi RW, Gallily T, Bialer M, Perucca E. Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know. Pharmacol Ther. 2021;226: 107866.

    Article  CAS  PubMed  Google Scholar 

  189. Fintepla® (fenfluramine) oral solution, CIV. FDA approved labeling text dated June 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212102s005lbl.pdf. Accessed 14 Feb 2023.

  190. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–8.

    Article  CAS  PubMed  Google Scholar 

  191. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339(11):713–8.

    Article  CAS  PubMed  Google Scholar 

  192. Astrup A. Drug management of obesity: efficacy versus safety. N Engl J Med. 2010;363(3):288–90.

    Article  CAS  PubMed  Google Scholar 

  193. Aicardi J, Gastaut H. Treatment of self-induced photosensitive epilepsy with fenfluramine. N Engl J Med. 1985;313(22):1419.

    Article  CAS  PubMed  Google Scholar 

  194. Casaer P, Boel M. Fenfluramine as a potential antiepileptic drug. Epilepsia. 2002;43(2):205–6.

    Article  PubMed  Google Scholar 

  195. Ceulemans B, Schoonjans AS, Marchau F, Paelinck BP, Lagae L. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):e129–34.

    Article  CAS  PubMed  Google Scholar 

  196. Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–54.

    Article  CAS  PubMed  Google Scholar 

  197. Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. FAiRE, DS Study Group. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–8.

    Article  PubMed  Google Scholar 

  198. Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79: e220829.

    Article  Google Scholar 

  199. Guerrini R, Specchio N, Aledo-Serrano Á, Pringsheim M, Darra F, Mayer T, et al. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: a report from the Fenfluramine European Early Access Program. Epilepsia Open. 2022. https://doi.org/10.1002/epi4.12624.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Sullivan J, Helen CJ. Raising the bar: fenfluramine sets new treatment standards for Dravet syndrome. Epilepsy Behav. 2021;121(Pt A): 108061.

    Article  PubMed  Google Scholar 

  201. Schedules of controlled substances: removal of fenfluramine from control. 21 CFR Part 1308. Effective December 23, 2022. https://www.federalregister.gov/documents/2022/12/23/2022-27400/schedules-of-controlled-substances-removal-of-fenfluramine-from-control. Accessed 8 Feb 2023.

  202. FDA drug safety communication: FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class. Accessed 9 Feb 2023.

  203. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356: j760.

    Article  PubMed  PubMed Central  Google Scholar 

  204. Vozoris NT. Benzodiazepine and opioid co-usage in the US population, 1999–2014: an exploratory analysis. Sleep. 2019;42(4):zsy264.

    Article  PubMed  Google Scholar 

  205. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.

    Article  CAS  PubMed  Google Scholar 

  206. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350: h2698.

    Article  PubMed  PubMed Central  Google Scholar 

  207. Bachhuber MA, Maughan BC, Mitra N, Feingold J, Starrels JL. Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: early evidence from 11 United States metropolitan areas. Int J Drug Policy. 2016;28:120–3.

    Article  PubMed  Google Scholar 

  208. McHugh RK, Geyer RB, Chase AR, Griffin ML, Bogunovic O, Weiss RD. Sex differences in benzodiazepine misuse among adults with substance use disorders. Addict Behav. 2021;112: 106608.

    Article  PubMed  Google Scholar 

  209. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136–42.

    Article  Google Scholar 

  210. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron. 2003;37:577–82.

    Article  CAS  PubMed  Google Scholar 

  211. Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463(7282):769–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  212. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315(14):854–9.

    Article  CAS  PubMed  Google Scholar 

  213. Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147–57.

    Article  CAS  PubMed  Google Scholar 

  214. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19–34.

    Article  CAS  PubMed  Google Scholar 

  215. Hayhoe B, Lee-Davey J. Tackling benzodiazepine misuse. BMJ. 2018;362: k3208.

    Article  PubMed  PubMed Central  Google Scholar 

  216. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728–34.

    Article  CAS  PubMed  Google Scholar 

  217. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. Accessed 22 Feb 2023.

  218. Lasser KE, Allen PD, Woolhandler SJ. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–20.

    Article  PubMed  Google Scholar 

  219. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328(1):29–33.

    Article  Google Scholar 

  220. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;6: CD001770.

    Google Scholar 

  221. USC355-1:Riskevaluationandmitigation strategies. https://uscode.house.gov/view.xhtml?req=(title:21%20section:355-1%20edition:prelim. Accessed 14 Feb 2023.

  222. Gassman AL, Nguyen CP, Joffe HV. FDA regulation of prescription drugs. N Engl J Med. 2017;376(7):674–82.

    Article  PubMed  Google Scholar 

  223. Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf. 2006;15(6):369–86.

    Article  PubMed  Google Scholar 

  224. Marcus SC, Olfson M, Pincus HA, Zarin DA, Kupfer DJ. Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. Am J Psychiatry. 1999;156(7):1014–8.

    Article  CAS  PubMed  Google Scholar 

  225. Ricci JR, Coulen C, Berger JE, Moore MC, McQueen A, Jan SA. Prescriber compliance with black box warnings in older adult patients. Am J Manag Care. 2009;15(11):e103–8.

    PubMed  Google Scholar 

  226. Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999;21(3):225–39.

    Article  CAS  PubMed  Google Scholar 

  227. Roberts JI, Metcalfe A, Abdulla F, Wiebe S, Hanson A, Federico P, et al. Neurologists’ and neurology residents’ knowledge of issues related to pregnancy for women with epilepsy. Epilepsy Behav. 2011;22(2):358–63.

    Article  PubMed  Google Scholar 

  228. Bell SG, Matsumoto M, Shaw SJ, Brandt J, Krauss GL. New antiepileptic drug safety information is not transmitted systematically and accepted by U.S. neurologists. Epilepsy Behav. 2013;29(1):36–40.

    Article  PubMed  Google Scholar 

  229. Smollin CG, Fu J, Levin R. Recognition and knowledge of medications with black box warnings among pediatricians and emergency physicians. J Med Toxicol. 2016;12(2):180–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Emory Healthcare, Emory Decatur Hospital, Decatur, GA, 30033, USA

    Abdul Wahab

  2. CVS Caremark, Woonsocket, RI, 02895, USA

    Attiya Iqbal

Authors
  1. Abdul Wahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Attiya Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdul Wahab.

Ethics declarations

Funding

No funding was received for the preparation of this article.

Conflicts of interest/competing interests

Abdul Wahab and Attiya Iqbal have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

This review is based on a literature search. All sources are included in the reference list.

Code availability

Not applicable.

Author contributions

The first draft of the manuscript was written by AW. Both authors contributed to the subsequent versions of the manuscript, and the literature search. Both authors read and approved the final manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wahab, A., Iqbal, A. Black-Box Warnings of Antiseizure Medications: What is Inside the Box?. Pharm Med 37, 233–250 (2023). https://doi.org/10.1007/s40290-023-00475-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-023-00475-x

Search

Navigation